{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:53:25Z","timestamp":1790877205385,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd012621","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T00:00:00Z","timestamp":1548892800000}}],"reference-count":185,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012621.pub2","type":"journal-article","created":{"date-parts":[[2019,1,31]],"date-time":"2019-01-31T07:52:32Z","timestamp":1548921152000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Phosphodiesterase 5 inhibitors for pulmonary hypertension"],"prefix":"10.1002","volume":"2019","author":[{"given":"Hayley","family":"Barnes","sequence":"first","affiliation":[{"name":"The Alfred Hospital; Department of Respiratory Medicine; Commercial Rd Melbourne Australia 3004"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Brown","sequence":"additional","affiliation":[{"name":"St Vincent's Hospital; Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Burns","sequence":"additional","affiliation":[{"name":"St Vincent's Hospital; Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Williams","sequence":"additional","affiliation":[{"name":"The Alfred Hospital; Department of Respiratory Medicine; Commercial Rd Melbourne Australia 3004"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,1,31]]},"reference":[{"key":"10.1002\/14651858.CD012621.pub2-BIB0001|cit1","first-page":"A3112","article-title":"Hemodynamic and exercise effects of different types of initial oral combination therapy in pulmonary arterial hypertension","volume":"195","author":"Albini","year":"2017","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012621.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1161\/CIRCULATIONAHA.110.016667","article-title":"A randomized, double-blind, placebo-controlled, dose-ranging study of oral sildenafil citrate in treatment-naive children with pulmonary arterial hypertension","volume":"125","author":"Barst","year":"2012","journal-title":"Circulation"},{"issue":"15","key":"10.1002\/14651858.CD012621.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/eurheartj\/ehx700","article-title":"Sildenafil for improving outcomes in patients with corrected valvular heart disease and persistent pulmonary hypertension: a multicenter, double-blind, randomized clinical trial","volume":"39","author":"Bermejo","year":"2018","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD012621.pub2-BIB0004|cit4","first-page":"55","article-title":"The efficacy and tolerability of sildenafil in patients with moderate-to-severe pulmonary hypertension","volume":"55","author":"Bharani","year":"2003","journal-title":"Indian Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD012621.pub2-BIB0005|cit5","first-page":"323","article-title":"Efficacy and safety of PDE-5 inhibitor tadalafil in pulmonary arterial hypertension","volume":"59","author":"Bharani","year":"2007","journal-title":"Indian Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD012621.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1183\/09031936.00176312","article-title":"Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial","volume":"42","author":"Blanco","year":"2013","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0007|cit7","first-page":"A2266","article-title":"Sildenafil treatment to improve the outcomes of pulmonary rehabilitation in COPD: A randomized, controlled trial","volume":"187","author":"Blanco","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine (Meeting Abstracts)"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0008|cit8","first-page":"3619","article-title":"Sildenafil citrate benefits patients with pulmonary arterial hypertension (PAH) across functional classes","volume":"26","author":"Boonstra","year":"2005","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"S128","DOI":"10.1016\/j.ihj.2015.10.323","article-title":"Assessment of short term effects of sildenafil therapy in patients with secondary pulmonary hypertension","volume":"67","author":"Dwivedi","year":"2015","journal-title":"Indian Heart Journal"},{"issue":"20","key":"10.1002\/14651858.CD012621.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMoa050010","article-title":"Sildenafil citrate therapy for pulmonary arterial hypertension","volume":"353","author":"Gali\u00e8","year":"2005","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0011|cit11","unstructured":"Peacock A Burgess G Parpia T Barst RJ Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients European Respiratory Society 15th Annual Congress; 2005 Sep 17-20; Copenhagen, Denmark 2005 Abstract No. 3127"},{"issue":"suppl 1","key":"10.1002\/14651858.CD012621.pub2-BIB0012|cit12","first-page":"442","article-title":"Effects of tadalafil on health-related quality of life in patients with pulmonary arterial hypertension","volume":"30","author":"Pepke-Zaba","year":"2009","journal-title":"European Heart Journal"},{"issue":"10","key":"10.1002\/14651858.CD012621.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1185\/03007990903210066","article-title":"Tadalafil therapy and health-related quality of life in pulmonary arterial hypertension","volume":"25","author":"Pepke-Zaba","year":"2009","journal-title":"Current Medical Research and Opinion"},{"key":"#cr-split#-10.1002\/14651858.CD012621.pub2-BIB0014|cit14.1","doi-asserted-by":"crossref","unstructured":"Pepke-Zaba J Brown M Parpia T Gilbert C Burgess G Sildenafil improves health-related quality of life in pulmonary arterial hypertension (PAH) patients European Respiratory Society Annual Congress. 2005 September 17-20","DOI":"10.1378\/chest.128.4_MeetingAbstracts.161S-a"},{"key":"#cr-split#-10.1002\/14651858.CD012621.pub2-BIB0014|cit14.2","unstructured":"Copenhagen, Denmark 2005 Abstract No. 848"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0015|cit15","unstructured":"Pepke-Zaba J Brown MCJ Parpia T Gilbert C Burgess G The impact of sildenafil citrate on health-related quality of life in patients with pulmonary arterial hypertension (PAH) results of a multicenter, multinational, randomized double-blind, placebo controlled trial American Thoracic Society International Conference; 2005 May 20-25; San Diego (CA) 2005 B16"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0016|cit16","doi-asserted-by":"crossref","unstructured":"Gali\u00e8 N Beardsworth A Wrishko RE Ghofrani HA Tadalafil improves exercise capacity in patients with pulmonary arterial hypertension across the interdosing interval American Thoracic Society International Conference; 2009 May 15-20; San Diego (CA) 2009 A1045","DOI":"10.1164\/ajrccm-conference.2009.179.1_MeetingAbstracts.A1045"},{"issue":"Suppl 58","key":"10.1002\/14651858.CD012621.pub2-BIB0017|cit17","first-page":"2916","article-title":"AMBITION: A randomised, multicenter study of first-line ambrisentan and tadalafil combination therapy in subjects with pulmonary arterial hypertension (PAH)","volume":"44","author":"Gali\u00e8","year":"2014","journal-title":"European Respiratory Journal"},{"issue":"9","key":"10.1002\/14651858.CD012621.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"Suppl 59","key":"10.1002\/14651858.CD012621.pub2-BIB0019|cit19","first-page":"OA4994","article-title":"Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naive patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population","volume":"46","author":"Hoeper","year":"2015","journal-title":"European Respiratory Journal"},{"issue":"4 suppl 2","key":"10.1002\/14651858.CD012621.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"339A","DOI":"10.1378\/chest.2056519","article-title":"Upfront combination therapy with ambrisentan and tadalafil in treatment naive patients with pulmonary arterial hypertension (PAH): Subgroup analyses by functional class (FC), etiology, and region from the ambition study","volume":"146","author":"Rubin","year":"2014","journal-title":"Chest"},{"issue":"5","key":"10.1002\/14651858.CD012621.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"487","DOI":"10.7775\/rac.es.v88.i5.19053","article-title":"In patients with pulmonary arterial hypertension treatment initiation with two drugs is associated with better outcome than with monotherapy: The AMBITION trial","volume":"83","author":"Thierer","year":"2015","journal-title":"Revista Argentina de Cardiologia"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0022|cit22","first-page":"A2197","article-title":"Initial combination therapy of ambrisentan and tadalafil reduced pulmonary arterial hypertension (PAH) related hospitalizations: Secondary analysis from the ambition trial","volume":"181","author":"Vachiery","year":"2015","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0023|cit23","first-page":"A2197","article-title":"Initial combination therapy of ambrisentan and tadalafil reduced pulmonary arterial hypertension (PAH) related hospitalizations: Secondary analysis from the ambition trial","volume":"191","author":"Vachiery","year":"2015","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0024|cit24","first-page":"A6468","article-title":"A randomized open label study comparing first-line treatment with bosentan or sildenafil in chronic thromboembolic pulmonary hypertension","volume":"193","author":"Gali\u00e8","year":"2016","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0025|cit25","unstructured":"Goudie A Hopkinson P Lipworth B Struthers A Do phosphodiesterase 5 inhibitors improve exercise capacity in patients with COPD associated pulmonary hypertension? (3P study) European Respiratory Society 23rd Annual Congress; 2013 September 7-11; Barcelona, Spain 2013"},{"issue":"4","key":"10.1002\/14651858.CD012621.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"293-300","DOI":"10.1016\/S2213-2600(14)70013-X","article-title":"Tadalafil in patients with chronic obstructive pulmonary disease: a randomised, double-blind, parallel-group, placebo-controlled trial","volume":"2","author":"Goudie","year":"2014","journal-title":"Lancet Respiratory Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012621.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.110.983866","article-title":"Pulmonary hypertension in heart failure with preserved ejection fraction: A target of phosphodiesterase-5 inhibition in a 1-year study","volume":"124","author":"Guazzi","year":"2011","journal-title":"Circulation"},{"issue":"6","key":"10.1002\/14651858.CD012621.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1378\/chest.12-1594","article-title":"Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction","volume":"143","author":"Han","year":"2013","journal-title":"Chest"},{"issue":"36","key":"10.1002\/14651858.CD012621.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1093\/eurheartj\/ehv336","article-title":"Effects of sildenafil on invasive haemodynamics and exercise capacity in heart failure patients with preserved ejection fraction and pulmonary hypertension: a randomized controlled trial","volume":"36","author":"Hoendermis","year":"2015","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1002\/14651858.CD012621.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1002\/ejhf.662","article-title":"Effects of sildenafil on cardiac structure and function, cardiopulmonary exercise testing and health-related quality of life measures in heart failure patients with preserved ejection fraction and pulmonary hypertension","volume":"19","author":"Liu","year":"2017","journal-title":"European Journal of Heart Failure"},{"issue":"9","key":"10.1002\/14651858.CD012621.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1093\/eurheartj\/ehq011","article-title":"Combination therapy with bosentan and sildenafil in Eisenmenger syndrome: A randomized, placebo-controlled, double-blinded trial","volume":"31","author":"Iversen","year":"2010","journal-title":"European Heart Journal"},{"issue":"26","key":"10.1002\/14651858.CD012621.pub2-BIB0032|cit32","first-page":"677-83","article-title":"Comparing the efficacy of tadalafil versus placebo on pulmonary artery systolic pressure and right ventricular function in patients with beta-thalassaemia intermedia","volume":"14","author":"Jalalian","year":"2016","journal-title":"Heart Lung and Circulation"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0033|cit33","first-page":"502","article-title":"Comparing the efficacy of tadalafil versus placebo on pulmonary artery systolic pressure and right ventricular function in patients with beta-thalassemia intermedia","volume":"36","author":"Jalalian","year":"2015","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0034|cit34","unstructured":"Jing ZC Yu ZX Shen JY Wu BX Xu KF Zhu XY Vardenafil therapy for pulmonary arterial hypertension: A randomised, double-blind, placebo-controlled, multicenter study European Society of Cardiology, ESC Congress; 2010 Aug 28-Sep 1; Stockholm, Sweden 2010"},{"issue":"12","key":"10.1002\/14651858.CD012621.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1164\/rccm.201101-0093OC","article-title":"Vardenafil in pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled study","volume":"183","author":"Jing","year":"2011","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012621.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1161\/CIRCULATIONAHA.106.626226","article-title":"Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure","volume":"115","author":"Lewis","year":"2007","journal-title":"Circulation"},{"issue":"14","key":"10.1002\/14651858.CD012621.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1161\/CIRCULATIONAHA.107.716373","article-title":"Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension","volume":"116","author":"Lewis","year":"2007","journal-title":"Circulation"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0038|cit38","unstructured":"Gladwin M Machado R Hassell K Yovetich N Gordeuk V Gibbs S Treatment of pulmonary hypertension (PH) and sickle cell disease (scd) with sildenafil (sild) therapy (walk-phasst): interim report European Respiratory Society 19th Annual Congress; 2009 September 12-15; Vienna, Austria 2009"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0039|cit39","doi-asserted-by":"crossref","unstructured":"Machado RF Barst RJ Yovetich NA Hassell KL Goldsmith JC Woolson R Evaluation of sildenafil therapy for patients with sickle cell disease and increased tricuspid regurgitant velocity: preliminary results of the walk-PHaSST trial American Thoracic Society International Conference; 2010 May 14-19; New Orleans (LA) 2010 A2514","DOI":"10.1164\/ajrccm-conference.2010.181.1_MeetingAbstracts.A2514"},{"issue":"22","key":"10.1002\/14651858.CD012621.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"Abstract no: 57","DOI":"10.1182\/blood.V114.22.571.571","article-title":"Safety and efficacy of sildenafil therapy for doppler-defined pulmonary hypertension in patients with sickle cell disease: preliminary results of the Walk-PHaSST clinical trial","volume":"114","author":"Machado","year":"2009","journal-title":"Blood"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0041|cit41","unstructured":"Yovetich NA Hassell KL Machado RF Barst RJ Gladwin MT Treatment of pulmonary hypertension and sickle cell disease with sildenafil therapy (walk-PHaSST): Background, rationale, study design, current enrollment and baseline data American Journal of Hematology Conference: 3rd Annual Sickle Cell Disease Research and Educational Symposium and Grant Writing Institute and Annual National Sickle Cell Disease Scientific Meeting; 2009 Feb 15-20; Fort Lauderdale (FL) 2009 E197 8"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0042|cit42","unstructured":"Mazzanti G Albini A Palazzini M Monti E Bachetti C Rinaldi A A randomized open label study comparing first-line treatment with bosentan or sildenafil in pulmonary arterial hypertension (PAH) European Society of Cardiology Annual Congress; 2013 Aug 31-Sep 4; Amsterdam, Netherlands 2013 A3535"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0043|cit43","doi-asserted-by":"crossref","unstructured":"Mazzanti G Palazzini M Dardi F Terzi F D'Adamo A Rinaldi A A randomized open label study comparing first-line treatment with bosentan or sildenafil in pulmonary arterial hypertension European Society of Congress; 2012 Aug 25-29; Munchen, Germany 2012 A4105","DOI":"10.1164\/ajrccm-conference.2012.185.1_MeetingAbstracts.A4105"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0044|cit44","first-page":"A3535","article-title":"A randomized open label study comparing first-line treatment with bosentan or sildenafil in pulmonary arterial hypertension (PAH): Long-term results","volume":"187","author":"Mazzanti","year":"2013","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012621.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1747-0803.2011.00561.x","article-title":"Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger Syndrome-A randomized, placebo-controlled, double-blind crossover study","volume":"6","author":"Mukhopadhyay","year":"2011","journal-title":"Congenital Heart Disease"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0046|cit46","unstructured":"Artem Ovchinnikov AG Potekhina AV Gavryushina SV Ageev FT Sildenafil improves functional capacity and exercise hemodynamics in patients with HFpEF and predominantly combined pre-and post-capillary pulmonary hypertension European Journal of Heart Failure Conference: Heart Failure 2018 and the 5th World Congress on Acute Heart Failure Austria 2018 567 8"},{"issue":"Suppl. 1","key":"10.1002\/14651858.CD012621.pub2-BIB0047|cit47","first-page":"5-441","article-title":"Phosphodiesterase-5 inhibitor sildenafil decreases pulmonary and left ventricular filling pressures and improves functional capacity in patients with diastolic heart failure and reactive pulmonary hypertension","volume":"17","author":"Ovchinnikov","year":"2015","journal-title":"European Journal of Heart Failure"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0048|cit48","doi-asserted-by":"crossref","unstructured":"Palazzini M Leci E Bachetti C Sgro F Mazzanti G Beciani E A randomized open label study comparing bosentan or sildenafil first-line treatment in pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) European Society of Cardiology Congress; 2010 Aug 28-Sep 1; Stockholm, Sweden 2010","DOI":"10.1164\/ajrccm-conference.2010.181.1_MeetingAbstracts.A3357"},{"issue":"Issue suppl_1,","key":"10.1002\/14651858.CD012621.pub2-BIB0049|cit49","first-page":"P759","article-title":"Clinical and haemodynamic effects of sildenafil in pulmonary hypertension secondary congenital systemic-to-pulmonary shunts and RV dysfunction","volume":"32","author":"Palii","year":"2011","journal-title":"European Heart Journal"},{"issue":"suppl 2","key":"10.1002\/14651858.CD012621.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"A31","DOI":"10.1136\/archdischild-2014-307384.93","article-title":"Outcome research in 77 patients with pulmonary arterial hypertension receiving sildenafil: A double-blind, randomised controlled study","volume":"99","author":"Palii","year":"2014","journal-title":"Archives of Disease in Childhood"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/eurheartj\/eht307.P298","article-title":"Efficacy of sildenafil therapy in children with pulmonary hypertension secondary to congenital systemic-to-pulmonary shunts","volume":"34","author":"Palii","year":"2013","journal-title":"European Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD012621.pub2-BIB0052|cit52","first-page":"81","article-title":"Sildenafil improves six-minute walk distance in chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial","volume":"53","author":"Rao","year":"2011","journal-title":"Indian Journal of Chest Diseases and Allied Sciences"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0053|cit53","unstructured":"Rao RS Singh S Sharma BB Singh V Does sildenafil improve exercise capacity and pulmonary artery hypertension in chronic obstructive pulmonary disease? A controlled trial European Respiratory Society 19th Annual Congress; 2009 Sep 12-15; Vienna, Austria 2009 P3850"},{"issue":"1","key":"10.1002\/14651858.CD012621.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ehj.2013.03.004","article-title":"Short term effects of sildenafil citrate therapy in secondary pulmonary hypertension","volume":"66","author":"Salem","year":"2014","journal-title":"Egyptian Heart Journal"},{"issue":"7","key":"10.1002\/14651858.CD012621.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.jacc.2003.10.056","article-title":"Clinical efficacy of sildenafil in primary pulmonary hypertension: A randomized, placebo-controlled, double-blind, crossover study","volume":"43","author":"Sastry","year":"2004","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0056|cit56","unstructured":"Simonneau G Burgess G Collings L Barst RJ Gali\u00e8 N Rubin LJ Safety and efficacy of combination therapy with sildenafil and epoprostenol in patients with pulmonary arterial hypertension (PAH) American Thoracic Society International Conference; 2006 May 19-21; San Diego 2006 A58"},{"issue":"8","key":"10.1002\/14651858.CD012621.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"521","DOI":"10.7326\/0003-4819-149-8-200810210-00004","article-title":"Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: A randomized trial","volume":"149","author":"Simonneau","year":"2008","journal-title":"Annals of Internal Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012621.pub2-BIB0058|cit58","first-page":"Abstract no:533","article-title":"A randomized, placebo-controlled, double blind, cross-over study to evaluate the efficacy and safety of oral sildenafil treatment in severe pulmonary artery hypertension","volume":"57","author":"Singh","year":"2005","journal-title":"Indian Heart Journal"},{"issue":"4","key":"10.1002\/14651858.CD012621.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"851.e1","DOI":"10.1016\/j.ahj.2005.09.006","article-title":"A randomized, placebo-controlled, double-blind, crossover study to evaluate the efficacy of oral sildenafil therapy in severe pulmonary artery hypertension","volume":"151","author":"Singh","year":"2006","journal-title":"American Heart Journal"},{"issue":"2","key":"10.1002\/14651858.CD012621.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1378\/chest.07-2681","article-title":"Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension","volume":"134","author":"Suntharalingam","year":"2008","journal-title":"Chest"},{"issue":"4","key":"10.1002\/14651858.CD012621.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1016\/j.healun.2014.01.398","article-title":"Spheric-1 (sildenafil and pulmonary hypertension in COPD): Intention-to-treat (ITT) analysis of safety and efficacy data","volume":"33","author":"Vitulo","year":"2014","journal-title":"Journal of Heart and Lung Transplantation"},{"issue":"Suppl 57","key":"10.1002\/14651858.CD012621.pub2-BIB0062|cit62","first-page":"5151","article-title":"COPD-associated severe pulmonary hypertension (COPDPH): Results of a 16-weeks prospective multicenter, double-blind, placebo-controlled randomized clinical trial (RCT) (SPHERIC-1 (clinicaltrials.gov\/ct2\/show\/NCT01441934)) investigating the effect of sildenafil citrate (Sld) on pulmonary vascular resistance (PVR) and PaO2","volume":"42","author":"Vitulo","year":"2013","journal-title":"European Respiratory Journal"},{"issue":"2","key":"10.1002\/14651858.CD012621.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.healun.2016.04.010","article-title":"Sildenafil in severe pulmonary hypertension associated with chronic obstructive pulmonary disease: A randomized controlled multicenter clinical trial","volume":"36","author":"Vitulo","year":"2016","journal-title":"Journal of Heart and Lung Transplantation"},{"issue":"1","key":"10.1002\/14651858.CD012621.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1186\/s12872-017-0674-3","article-title":"Sildenafil dosed concomitantly with bosentan for adult pulmonary arterial hypertension in a randomized controlled trial","volume":"17","author":"Vizza","year":"2017","journal-title":"BMC Cardiovascular Disorders"},{"issue":"11","key":"10.1002\/14651858.CD012621.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1164\/rccm.200410-1411OC","article-title":"Sildenafil versus endothelin receptor antagonist for pulmonary hypertension (SERAPH) study","volume":"171","author":"Wilkins","year":"2005","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"6","key":"10.1002\/14651858.CD012621.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/hr.2014.28","article-title":"Randomized study of adding tadalafil to existing ambrisentan in pulmonary arterial hypertension","volume":"37","author":"Zhuang","year":"2014","journal-title":"Hypertension Research"},{"issue":"8","key":"10.1002\/14651858.CD012621.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1136\/thx.2005.041954","article-title":"Phosphodiesterase type 5 and high altitude pulmonary hypertension","volume":"60","author":"Aldashev","year":"2005","journal-title":"Thorax"},{"issue":"4","key":"10.1002\/14651858.CD012621.pub2-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.ejcdt.2016.05.005","article-title":"Sildenafil citrate therapy for secondary pulmonary arterial hypertension due to chronic obstructive lung disease","volume":"65","author":"Alkhayat","year":"2016","journal-title":"Egyptian Journal of Chest Diseases and Tuberculosis"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"367A","DOI":"10.1378\/chest.10870","article-title":"Tadalafil in geriatric patients with pulmonary arterial hypertension","volume":"138","author":"Arneson","year":"2010","journal-title":"Chest"},{"issue":"Meeting Abstrac","key":"10.1002\/14651858.CD012621.pub2-BIB0070|cit70","first-page":"A4779","article-title":"Comparison between initial combination therapy and initial monotherapy in pulmonary arterial hypertension: a single centre blinded evaluation of patients enrolled in the AMBITION study","volume":"191","author":"Bachetti","year":"2015","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0071|cit71","first-page":"967","article-title":"Hemodynamic effect of initial combination therapy as compared to initial monotherapy in pulmonary arterial hypertension: A single centre blinded evaluation of patients enrolled in the AMBITION study","volume":"36","author":"Bachetti","year":"2015","journal-title":"European Heart Journal"},{"issue":"8","key":"10.1002\/14651858.CD012621.pub2-BIB0072|cit72","first-page":"A57 [Poster: K3","article-title":"Sildenafil citrate in patients with pulmonary arterial hypertension (PAH) results of a multicenter multinational randomized double-blind placebo controlled trial by WHO functional class (FC)","volume":"60","author":"Badesch","year":"2005","journal-title":"Thorax"},{"issue":"12","key":"10.1002\/14651858.CD012621.pub2-BIB0073|cit73","first-page":"2417","article-title":"Sildenafil for pulmonary arterial hypertension associated with connective tissue disease","volume":"34","author":"Badesch","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0074|cit74","unstructured":"Badesch D Hwang LJ Teal S Cwengros J Watt S Posthoc subgroup analysis: Sildenafil (SIL) added to long-term epoprostenol therapy in patients with idiopathic and connective tissue disease (CTD)-associated pulmonary arterial hypertension (PAH) European Society of Cardiology Congress; 2011 Aug 27-31; Paris, France 2011 173, 1179"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0075|cit75","unstructured":"Barst R Brundage B Ghofrani A Oudiz R Simmoneau G Beardsworth A European Respiratory Society 18th Annual Congress; 2008 Oct 3-7; Berlin, Germany 2008 3176"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0076|cit76","doi-asserted-by":"crossref","unstructured":"Barst RJ Brundage BH Ghofrani A Oudiz RJ Simonneau G Beardsworth A Tadalafil improves exercise capacity, health related quality of life and delays time to clinical worsening in patients with symptomatic pulmonary arterial hypertension (PAH) [Abstract] 2008 39003s","DOI":"10.1378\/chest.134.4_MeetingAbstracts.s39003"},{"issue":"6","key":"10.1002\/14651858.CD012621.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.healun.2010.11.009","article-title":"Pulmonary arterial, hypertension; response to tadalafil study, group - tadalafil monotherapy and as add-on to background bosentan in patients with pulmonary arterial hypertension","volume":"30","author":"Barst","year":"2011","journal-title":"Journal of Heart and Lung Transplantation"},{"issue":"3","key":"10.1002\/14651858.CD012621.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1089\/ham.2011.0007","article-title":"Sildenafil citrate for the prevention of high altitude hypoxic pulmonary hypertension: double blind, randomized, placebo-controlled trial","volume":"12","author":"Bates","year":"2011","journal-title":"High Altitude Medicine and Biology"},{"issue":"12","key":"10.1002\/14651858.CD012621.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/j.healun.2011.08.019","article-title":"Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension","volume":"30","author":"Benza","year":"2011","journal-title":"Journal of Heart and Lung Transplantation"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/2045893217741480","article-title":"Bosentan-based, treat-to-target therapy in patients with pulmonary arterial hypertension: results from the COMPASS-3 study","volume":"8","author":"Benza","year":"2018","journal-title":"Pulmonary Circulation"},{"issue":"7","key":"10.1002\/14651858.CD012621.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.healun.2009.04.013","article-title":"Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition","volume":"28","author":"Botha","year":"2009","journal-title":"Journal of Heart and Lung Transplantation"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0082|cit82","unstructured":"Butrous G Ghofrani HA Weissmann N Schermuly Seeger W Grimminger F Oral sildenafil is a potent pulmonary vasodilator and improves gas exchange in patients with COPD with pulmonary hypertension European Respiratory Society 16th Annual Congress; 2006 Sep 3-6; Munich, Germany 2006 426s [P2494]"},{"issue":"4","key":"10.1002\/14651858.CD012621.pub2-BIB0083|cit83","doi-asserted-by":"crossref","first-page":"362A","DOI":"10.1378\/chest.10285","article-title":"Physical functioning, six-minute walk distance, and pulmonary vascular resistance in adult patients with pulmonary arterial hypertension treated with sildenafil: examining the distributions of outcomes","volume":"138","author":"Cappelleri","year":"2010","journal-title":"Chest"},{"issue":"7","key":"10.1002\/14651858.CD012621.pub2-BIB0084|cit84","doi-asserted-by":"crossref","first-page":"A367","DOI":"10.1016\/S1098-3015(11)72479-2","article-title":"PCV138 Measurement properties of peak VO2 in children with pulmonary arterial hypertension","volume":"13","author":"Cappelleri","year":"2010","journal-title":"Value in Health"},{"issue":"7","key":"10.1002\/14651858.CD012621.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"A343","DOI":"10.1016\/S1098-3015(11)72360-9","article-title":"PCV17 Response profiles of sildenafil citrate on exercise capacity, hemodynamic function, and health-related quality of life in children with pulmonary arterial hypertension","volume":"13","author":"Cappelleri","year":"2010","journal-title":"Value in Health"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0086|cit86","first-page":"A4812","article-title":"A multinational, randomized, double-blind trial of sitaxentan monotherapy compared with sitaxentan in combination with sildenafil in patients with pulmonary arterial hypertension: The sitaxentan randomized prospective assessment adding sildenafil (SR-PAAS)","volume":"185","author":"Chin","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0087|cit87","unstructured":"Corris PA Burgess G Parpia T Barst RJ Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH) European Respiratory Society 15th Annual Congress; 2005 Sep 17-20; Copenhagen, Denmark 2005 Abstract No. 3128"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0088|cit88","unstructured":"Dandekar PG Verma Y Efficacy and safety profile of phosphodiesterase 5 inhibitor sildenafil in pulmonary hypertension International Congress of Cardiology; 2012 Feb 24-26; Hong Kong 2012 A7"},{"issue":"1","key":"10.1002\/14651858.CD012621.pub2-BIB0089|cit89","first-page":"19","article-title":"Additive effect of phosphodiesterase inhibitors in control of pulmonary hypertension after congenital cardiac surgery in children","volume":"23","author":"Farah","year":"2013","journal-title":"Iranian Journal of Pediatrics"},{"issue":"2","key":"10.1002\/14651858.CD012621.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1016\/j.healun.2008.11.581","article-title":"Sildenafil or bosentan in patients considered inelegible for heart transplantation because of severe pulmonary hypertension","volume":"28","author":"Farrero","year":"2009","journal-title":"Journal of Heart and Lung Transplantation"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"364A","DOI":"10.1378\/chest.10593","article-title":"Does 16-week response predict long-term success? Results from a 52-week analysis of patients receiving 40 mg once-daily tadalafil","volume":"138","author":"Feldman","year":"2010","journal-title":"Chest"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s12955-014-0130-3","article-title":"Quality of life as a prognostic marker in pulmonary arterial hypertension","volume":"12","author":"Fernandes","year":"2014","journal-title":"Health and Quality of Life Outcomes"},{"issue":"4","key":"10.1002\/14651858.CD012621.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1164\/rccm.200808-1348OC","article-title":"Dexamethasone but not tadalafil improves exercise capacity in adults prone to high-altitude pulmonary edema","volume":"180","author":"Fischler","year":"2009","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0094|cit94","unstructured":"Gali\u00e8 N Burgess G Parpia T Barst R Effects of sildenafil on 1 year survival of patients with idiopathic pulmonary arterial hypertension (PAH) American Thoracic Society International Conference; 2005 May 20-25; San Diego (CA) 2005 C88"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"734A","DOI":"10.1378\/chest.1111111","article-title":"Long-term outcomes of patients with pulmonary arterial hypertension associated with connective tissue disease as compared with idiopathic or heritable pulmonary arterial hypertension treated with tadalafil","volume":"140","author":"Gali\u00e8","year":"2011","journal-title":"Chest"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0096|cit96","first-page":"412s (P2299)","article-title":"Tadalafil in idiopathic or heritable pulmonary arterial hypertension compared to pulmonary arterial hypertension associated with connective tissue disease","volume":"38","author":"Gali\u00e8","year":"2011","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/eurheartj\/eht307.P338","article-title":"Long-term safety and survival outcomes of patients with pulmonary arterial hypertension enrolled in an open label continuation study with tadalafil 40mg daily","volume":"34","author":"Gali\u00e8","year":"2013","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0098|cit98","unstructured":"Ghofrani AH Wiedermann R Rose F Schermuly T Olschewski H Weissmann N Sildenafil is a potent pulmonary vasodilator in pulmonary hypertension associated with interstitial lung disease: impact on gas exchange properties European Respiratory Society 18th Annual Congress; 2008 October 3-7; Berlin, Germany 2008"},{"issue":"7","key":"10.1002\/14651858.CD012621.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"515","DOI":"10.7326\/0003-4819-136-7-200204020-00008","article-title":"Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension","volume":"136","author":"Ghofrani","year":"2002","journal-title":"Annals of Internal Medicine"},{"issue":"9337","key":"10.1002\/14651858.CD012621.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/S0140-6736(02)11024-5","article-title":"Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial (see comment)","volume":"360","author":"Ghofrani","year":"2002","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0101|cit101","doi-asserted-by":"crossref","unstructured":"Ghofrani HA Reichenberger F Kohstall MG Mrosek E Seeger T Schermuly RT Sildenafil reduces hypoxia-induced pulmonary hypertension and increases exercise capacity during oxygen deprivation at a low altitude and at Mount Everest base camp: a randomized placebo controlled study American Thoracic Society 100th International Conference; 2004 May 21-26; Orlando (FL) 2004 A56 Poster B3","DOI":"10.7326\/0003-4819-141-3-200408030-00005"},{"issue":"7","key":"10.1002\/14651858.CD012621.pub2-BIB0102|cit102","first-page":"1488-96","article-title":"Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension - a randomized prospective study","volume":"44","author":"Ghofrani","year":"2004","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"10.1002\/14651858.CD012621.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"169","DOI":"10.7326\/0003-4819-141-3-200408030-00005","article-title":"Sildenafil increased exercise capacity during hypoxia at low altitudes and at Mount Everest base camp: a randomized, double-blind, placebo-controlled crossover trial","volume":"141","author":"Ghofrani","year":"2004","journal-title":"Annals of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012621.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"55S","DOI":"10.1378\/chest.136.4_MeetingAbstracts.55S-a","article-title":"Tadalafil in patients with collagen vascular disease-associated pulmonary arterial hypertension","volume":"136","author":"Girgis","year":"2009","journal-title":"Chest"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0105|cit105","first-page":"208","article-title":"A randomized open label study comparing first-line treatment with bosentan or sildenafil in chronic thromboembolic pulmonary hypertension (CTEPH)","volume":"35","author":"Gotti","year":"2014","journal-title":"European Heart Journal"},{"issue":"22","key":"10.1002\/14651858.CD012621.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"2136-44","DOI":"10.1016\/j.jacc.2007.07.078","article-title":"Long-term use of sildenafil in the therapeutic management of heart failure","volume":"50","author":"Guazzi","year":"2007","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"A14722","DOI":"10.1161\/CIRCULATIONAHA.110.983866","article-title":"A long term follow-up study of patients with mild to moderate group 2 pulmonary hypertension treated with Pde5-inhibition: A comparison between heart failure with reduced and preserved ejection fraction","volume":"124","author":"Guazzi","year":"2011","journal-title":"Circulation"},{"issue":"5","key":"10.1002\/14651858.CD012621.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1002\/ejhf.753","article-title":"Is sildenafil neutral on cardiopulmonary performance in group 2 pulmonary hypertension? More details for interpretation","volume":"19","author":"Guazzi","year":"2017","journal-title":"European Journal of Heart Failure"},{"issue":"2","key":"10.1002\/14651858.CD012621.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00408-009-9209-8","article-title":"Sildenafil therapy and exercise tolerance in idiopathic pulmonary fibrosis","volume":"188","author":"Jackson","year":"2010","journal-title":"Lung"},{"issue":"18","key":"10.1002\/14651858.CD012621.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.jacc.2010.01.027","article-title":"Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial","volume":"55","author":"McLaughlin","year":"2010","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0111|cit111","doi-asserted-by":"crossref","unstructured":"McLaughlin V Channick R Ghofrani HA LeMarie JC Naeije R Packer M Effect of bosentan and sildenafil combination therapy on morbidity and mortality in pulmonary arterial hypertension (PAH): Results from the compass-2 study Chest 2014 860A","DOI":"10.1378\/chest.1992777"},{"issue":"2","key":"10.1002\/14651858.CD012621.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1183\/13993003.02044-2014","article-title":"Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension","volume":"46","author":"McLaughlin","year":"2015","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0113|cit113","first-page":"A3336","article-title":"Evaluation of sildenafil treatment on functional health status in patients with pulmonary arterial hypertension","volume":"181","author":"Mychaskiw","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012621.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"363A","DOI":"10.1378\/chest.10331","article-title":"Relationship between pulmonary vascular resistance and physical functioning in two randomized controlled trials of adult patients with pulmonary arterial hypertension, including those with associated connective tissue disease","volume":"138","author":"Mychaskiw","year":"2010","journal-title":"Chest"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0115|cit115","unstructured":"Nazeem T Thomas S Kumar S Severity based clinical efficacy and safety of oral sildenafil in the management of pulmonary arterial hypertension - a pilot study Nepal Journal of Epidemiology 2014"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0116|cit116","unstructured":"Oudiz R Ghofrani HA Simonneau G Barst R Brundage B Elion-Mboussa A The effect of once-daily tadalafil on exercise capacity and clinical deterioration with up to 68 weeks of treatment in patients with pulmonary arterial hypertension (PAH) European Society of Cardiology Congress 2009; 2009 August 28-September 2; Barcelona, Spain 2009 899"},{"issue":"4","key":"10.1002\/14651858.CD012621.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"55S","DOI":"10.1378\/chest.136.4_MeetingAbstracts.55S-b","article-title":"Long-term improvements in clinical worsening with tadalafil in patients with pulmonary arterial hypertension","volume":"136","author":"Oudiz","year":"2009","journal-title":"Chest"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0118|cit118","first-page":"A1042 (Poster #","article-title":"Blinded, long-term safety and efficacy of tadalafil in treatment for pulmonary arterial hypertension","volume":"179","author":"Oudiz","year":"2009","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0119|cit119","unstructured":"Oudiz RJ Brundage B Galie N Simonneau G Barst RB Elion-Mboussa A Effect of once-daily tadalafil on exercise capacity and clinical deterioration with up to 68 weeks of treatment in patients with PAH European Respiratory Society 19th Annual Congress; 2009 Sep 12-15; Vienna 2009 [E1486]"},{"issue":"8","key":"10.1002\/14651858.CD012621.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/j.jacc.2012.05.004","article-title":"Tadalafil for the treatment of pulmonary arterial hypertension: a double-blind 52-week uncontrolled extension study","volume":"60","author":"Oudiz","year":"2012","journal-title":"Journal of the American College of Cardiology"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0121|cit121","unstructured":"Peacock A Burgess G Parpia T Barst RJ Hemodynamic effects of sildenafil in pulmonary arterial hypertension (PAH) patients European Respiratory Society 15th Annual Congress; 2005 September 17-20; Copenhagen, Denmark 2005 Abstract No. 3127"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0122|cit122","first-page":"743","article-title":"Pulmonary arterial hypertension and sildenafil: A second stage control","volume":"35","author":"Roig","year":"2014","journal-title":"European Heart Journal"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0123|cit123","unstructured":"Rubin L Burgess G Parpia T Simoneau G Effects of sildenafil on 6 minute walk distance (6MWD) and WHO functional class (FC) after 1 year of treatment American Thoracic Society 2005 International Conference; 2005 May 20-25; San Diego (CA) 2005 B16"},{"issue":"5","key":"10.1002\/14651858.CD012621.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1378\/chest.10-0969","article-title":"Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study","volume":"140","author":"Rubin","year":"2011","journal-title":"Chest"},{"issue":"1","key":"10.1002\/14651858.CD012621.pub2-BIB0125|cit125","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.acmx.2014.11.006","article-title":"Combined treatment of sildenafil and inhaled iloprost in pediatric patients with severe pulmonary arterial hypertension","volume":"85","author":"Santos-Martinez","year":"2015","journal-title":"Archivos de Cardiologia de Mexico"},{"issue":"5","key":"10.1002\/14651858.CD012621.pub2-BIB0126|cit126","first-page":"143","article-title":"Sildenafil citrate in patients with primary-pulmonary hypertension","volume":"54","author":"Shamma","year":"2002","journal-title":"Indian Heart Journal"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0127|cit127","first-page":"A1892","article-title":"Comparison of efficacy of different treatment regimens in pulmonary hypertension secondary to lung disease and\/or hypoxia","volume":"189","author":"Sharma","year":"2014","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"60","key":"10.1002\/14651858.CD012621.pub2-BIB0128|cit128","first-page":"271","article-title":"Effect of sildenafil citrate on pulmonary arterial systolic pressure and sub-maximal exercise capacity in chronic obstructive pulmonary disease","volume":"15","author":"Shrestha","year":"2017","journal-title":"Kathmandu University Medical Journal (KUMJ)"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0129|cit129","first-page":"A3332","article-title":"Long-term oral sildenafil added to intravenous epoprostenol therapy improves outcomes in patients with pulmonary arterial hypertension","volume":"181","author":"Simonneau","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"Suppl 49","key":"10.1002\/14651858.CD012621.pub2-BIB0130|cit130","first-page":"3129","article-title":"Effects of sildenafil on 6-minute walk distance (6MWD) and WHO functional class (FC) in pulmonary arterial hypertension (PAH) patients after 1 year of treatment","volume":"26","author":"Sitbon","year":"2005","journal-title":"European Respiratory Journal"},{"issue":"6","key":"10.1002\/14651858.CD012621.pub2-BIB0131|cit131","first-page":"414","article-title":"Clinical study on sildenafil in treatment of pregnant women with pulmonary arterial hypertension","volume":"49","author":"Sun","year":"2014","journal-title":"Chung-hua Fu Chan Ko Tsa Chih (Chinese Journal of Obstetrics & Gynaecology)"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0132|cit132","first-page":"e44","article-title":"Tadalafil in out-of-proportion pulmonary hypertension secondary to left ventricular dysfunction: Rationale and design of the study","volume":"12","author":"Vizza","year":"2011","journal-title":"Giornale Italiano di Cardiologia"},{"issue":"1","key":"10.1002\/14651858.CD012621.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12890-017-0374-x","article-title":"Efficacy of 1, 5, and 20 mg oral sildenafil in the treatment of adults with pulmonary arterial hypertension: a randomized, double-blind study with open-label extension","volume":"17","author":"Vizza","year":"2017","journal-title":"BMC Pulmonary Medicine"},{"issue":"9","key":"10.1002\/14651858.CD012621.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1177\/0091270011418656","article-title":"Impact of sildenafil on survival of patients with idiopathic pulmonary arterial hypertension","volume":"52","author":"Zeng","year":"2012","journal-title":"Journal of Clinical Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD012621.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1093\/eurjhf\/hfs152","article-title":"Sildenafil in heart failure (SilHF). An investigator-initiated multinational randomized controlled clinical trial: Rationale and design","volume":"15","author":"Cooper","year":"2013","journal-title":"European Journal of Heart Failure"},{"issue":"4","key":"10.1002\/14651858.CD012621.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1086\/674759","article-title":"Study design and rationale for investigating phosphodiesterase type 5 inhibition for the treatment of pulmonary hypertension due to chronic obstructive lung disease: the TADA-PHiLD (TADAlafil for Pulmonary Hypertension associated with chronic obstructive Lung Disease) trial","volume":"3","author":"Maron","year":"2013","journal-title":"Pulmonary Circulation"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.rmed.2018.03.019","article-title":"Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design","volume":"138","author":"Behr","year":"2018","journal-title":"Respiratory Medicine"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0138|cit138","unstructured":"NCT02951429 Efficacy, safety, and tolerability study of pirfenidone in combination with sildenafil in participants with advanced idiopathic pulmonary fibrosis (IPF) and risk of group 3 pulmonary hypertension clinicaltrials.gov\/ct2\/show\/NCT02951429"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0139|cit139","unstructured":"Jianguo He The safety and efficiency of sildenafil in the treatment of severe post-capillary pulmonary hypertension caused by COPD NCT03185364 2017"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0140|cit140","first-page":"PA2417","article-title":"REPLACE: a prospective, randomized trial of riociguat replacing phosphodiesterase 5 inhibitor therapy in patients with pulmonary arterial hypertension who are not at treatment goal","volume":"50","author":"Hoeper","year":"2017","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0141|cit141","unstructured":"Hoeper MM Ghofrani HA Benza RL Corris PA Gibbs S Klinger JR Rationale and design of the REPLACE trial: riociguat replacing phosphodiesterase 5 inhibitor (PDE5i) therapy evaluated against continued PDE5i therapy in patients with pulmonary arterial hypertension (PAH) American journal of respiratory and critical care medicine 2017 A2296"},{"issue":"9","key":"10.1002\/14651858.CD012621.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1056\/NEJMoa1413687","article-title":"Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension","volume":"373","author":"Gali\u00e8","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"19","key":"10.1002\/14651858.CD012621.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1056\/NEJMct0904473","article-title":"Phosphodiesterase type 5 inhibitors for pulmonary arterial hypertension","volume":"361","author":"Archer","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD012621.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"270-8","DOI":"10.1164\/rccm.200907-0988OC","article-title":"Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension","volume":"181","author":"Blanco","year":"2010","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012621.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"70-2","DOI":"10.1016\/0002-9149(94)90496-0","article-title":"Inhaled nitric oxide leading to pulmonary edema in stable severe heart failure","volume":"74","author":"Bocchi","year":"1994","journal-title":"American Journal of Cardiology"},{"issue":"2","key":"10.1002\/14651858.CD012621.pub2-BIB0146|cit146","doi-asserted-by":"crossref","first-page":"1700889","DOI":"10.1183\/13993003.00889-2017","article-title":"Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension","volume":"50","author":"Boucly","year":"2017","journal-title":"European Respiratory Journal"},{"issue":"2","key":"10.1002\/14651858.CD012621.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1183\/13993003.02044-2014","article-title":"Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension","volume":"46","author":"McLaughlin","year":"2014","journal-title":"European Respiratory Journal"},{"issue":"2","key":"10.1002\/14651858.CD012621.pub2-BIB0148|cit148","doi-asserted-by":"crossref","first-page":"266-71","DOI":"10.1161\/01.CIR.93.2.266","article-title":"Role of nitric oxide in the local regulation of pulmonary vascular resistance in humans","volume":"93","author":"Cooper","year":"1996","journal-title":"Circulation"},{"issue":"9","key":"10.1002\/14651858.CD012621.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"859-71","DOI":"10.1161\/CIRCULATIONAHA.115.016522","article-title":"Long-term outcome of patients with chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry","volume":"133","author":"Delcroix","year":"2016","journal-title":"Circulation"},{"issue":"2","key":"10.1002\/14651858.CD012621.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1751-7133.2010.00202.x","article-title":"REVEAL Registry: correlation of right heart catheterization and echocardiography in patients with pulmonary arterial hypertension","volume":"17","author":"Farber","year":"2011","journal-title":"Congestive Heart Failure"},{"issue":"6","key":"10.1002\/14651858.CD012621.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1177\/1074248414528066","article-title":"Conversion From sildenafil to tadalafil: Results from the sildenafil to tadalafil in pulmonary arterial hypertension (SITAR) Study","volume":"19","author":"Frantz","year":"2014","journal-title":"Journal of Cardiovascular Pharmacology and Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD012621.pub2-BIB0152|cit152","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1183\/09031936.00105914","article-title":"PATENT PLUS: a blinded, randomised and extension study of riociguat plus sildenafil in pulmonary arterial hypertension","volume":"45","author":"Gali\u00e8","year":"2015","journal-title":"European Respiratory Journal"},{"issue":"2","key":"10.1002\/14651858.CD012621.pub2-BIB0153|cit153","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.recesp.2016.01.002","article-title":"2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"69","author":"Gali\u00e8","year":"2016","journal-title":"Revista Espanola de Cardiologia"},{"issue":"12 Suppl S","key":"10.1002\/14651858.CD012621.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"68S","DOI":"10.1016\/j.jacc.2004.02.031","article-title":"Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension","volume":"43","author":"Ghofrani","year":"2004","journal-title":"Journal of the American College of Cardiology"},{"issue":"4","key":"10.1002\/14651858.CD012621.pub2-BIB0155|cit155","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa1209657","article-title":"Riociguat for the treatment of chronic thromboembolic pulmonary hypertension","volume":"369","author":"Ghofrani","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012621.pub2-BIB0156|cit156","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1378\/chest.07-0275","article-title":"Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil","volume":"135","author":"Gilbert","year":"2009","journal-title":"Chest"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0157|cit157","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2015"},{"issue":"26","key":"10.1002\/14651858.CD012621.pub2-BIB0158|cit158","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1056\/NEJMoa1503184","article-title":"Selexipag for the treatment of pulmonary arterial hypertension","volume":"373","author":"Sitbon","year":"2015","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"10.1002\/14651858.CD012621.pub2-BIB0159|cit159","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1161\/CIRCULATIONAHA.111.085761","article-title":"Pulmonary hypertension due to left heart disease","volume":"126","author":"Guazzi","year":"2012","journal-title":"Circulation"},{"issue":"130","key":"10.1002\/14651858.CD012621.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1183\/09059180.00007513","article-title":"Pathogenesis of pulmonary arterial hypertension: lessons from cancer","volume":"22","author":"Guignabert","year":"2013","journal-title":"European Respiratory Review"},{"issue":"12","key":"10.1002\/14651858.CD012621.pub2-BIB0161|cit161","first-page":"1441","article-title":"Measuring quality of life in clinical trials: a taxonomy and review","volume":"140","author":"Guyatt","year":"1989","journal-title":"Canadian Medical Association Journal"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0162|cit162","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0163|cit163","unstructured":"Higgins JP Altmam DG Sterne JA (editors) on behalf of the Cochrane Statistical Methods Group and the Cochrane Bias Methods Group Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors), Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"issue":"2","key":"10.1002\/14651858.CD012621.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"1700740","DOI":"10.1183\/13993003.00740-2017","article-title":"Mortality in pulmonary arterial hypertension: prediction by the 2015 European pulmonary hypertension guidelines risk stratification model","volume":"50","author":"Hoeper","year":"2017","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"680-5","DOI":"10.1016\/j.hlc.2013.12.014","article-title":"Effects of sildenafil on prognosis inpatients with pulmonary hypertension after left-sided valvular surgery","volume":"23","author":"Jiang","year":"2014","journal-title":"Heart Lung Circulation"},{"issue":"6","key":"10.1002\/14651858.CD012621.pub2-BIB0166|cit166","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1513\/AnnalsATS.201512-824OC","article-title":"The minimal important difference in borg dyspnea score in pulmonary arterial hypertension","volume":"13","author":"Khair","year":"2016","journal-title":"Annals of the American Thoracic Society"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0167|cit167","doi-asserted-by":"crossref","unstructured":"Kylhammar D Kjellstr\u00f6m B Hjalmarsson C Jansson K Nisell M S\u00f6derberg S A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension European Heart Journal 2018 4175 81 10.1093\/eurheartj\/ehx257","DOI":"10.1093\/eurheartj\/ehx257"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"2353-62","DOI":"10.1161\/CIRCULATIONAHA.111.081125","article-title":"Effects of phosphodiesterase type5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosis","volume":"125","author":"Lindman","year":"2012","journal-title":"Circulation"},{"issue":"8","key":"10.1002\/14651858.CD012621.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1164\/rccm.201203-0383OC","article-title":"Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United Kingdom and Ireland","volume":"186","author":"Ling","year":"2012","journal-title":"American Journal of Respiratory and Critical Care Medicine"},{"issue":"17","key":"10.1002\/14651858.CD012621.pub2-BIB0170|cit170","doi-asserted-by":"crossref","first-page":"1573-619","DOI":"10.1016\/j.jacc.2009.01.004","article-title":"ACCF\/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on expert consensus documents","volume":"53","author":"McLaughlin","year":"2009","journal-title":"Journal of the American College of Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD012621.pub2-BIB0171|cit171","doi-asserted-by":"publisher","first-page":"e1000097","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012621.pub2-BIB0172|cit172","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1183\/09031936.00092306","article-title":"An epidemiological study of pulmonary arterial hypertension","volume":"30","author":"Peacock","year":"2007","journal-title":"European Respiratory Journal"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0173|cit173","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"key":"10.1002\/14651858.CD012621.pub2-BIB0174|cit174","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Akl E on behalf of the Cochrane GRADEing Methods Group and the Cochrane Statistical Methods Group Chapter 11: Completing \u2018Summary of findings\u2019 tables and grading the confidence in or quality of the evidence. In: Higgins JP, Churchill R, Chandler J, Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017). Cochrane, 2017 Available from www.training.cochrane.org\/handbook"},{"issue":"9","key":"10.1002\/14651858.CD012621.pub2-BIB0175|cit175","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.1002\/14651858.CD012621.pub2-BIB0176|cit176","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4097\/kjae.2010.58.1.4","article-title":"Nitric oxide and pulmonary hypertension","volume":"58","author":"Sim","year":"2010","journal-title":"Korean Journal of Anesthesiology"},{"issue":"3","key":"10.1002\/14651858.CD012621.pub2-BIB0177|cit177","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1097\/MAJ.0b013e31827871dc","article-title":"Pulmonary hypertension and idiopathic pulmonary fibrosis: a dastardly duo","volume":"346","author":"Smith","year":"2013","journal-title":"American Journal of Medical Science"},{"issue":"4","key":"10.1002\/14651858.CD012621.pub2-BIB0178|cit178","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1136\/heartjnl-2012-301992","article-title":"Pulmonary hypertension: prevalence and mortality in the Armadale echocardiography cohort","volume":"98","author":"Strange","year":"2012","journal-title":"Heart"},{"issue":"6","key":"10.1002\/14651858.CD012621.pub2-BIB0179|cit179","doi-asserted-by":"crossref","first-page":"1103-10","DOI":"10.1183\/09031936.00042107","article-title":"A USA-based registry for pulmonary arterial hypertension: 1982-2006","volume":"30","author":"Thenappan","year":"2007","journal-title":"European Respiratory Journal"},{"issue":"25 Suppl","key":"10.1002\/14651858.CD012621.pub2-BIB0180|cit180","doi-asserted-by":"crossref","first-page":"D100","DOI":"10.1016\/j.jacc.2013.10.033","article-title":"Pulmonary hypertension due to left heart diseases","volume":"62","author":"Vachi\u00e9ry","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"7","key":"10.1002\/14651858.CD012621.pub2-BIB0181|cit181","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1056\/NEJMoa1002110","article-title":"A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis","volume":"363","author":"Zisman","year":"2010","journal-title":"New England Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD012621.pub2-BIB0182|cit182","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012621","article-title":"Phosphodiesterase 5 inhibitors for pulmonary hypertension","author":"Barnes","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD012621.pub2-BIB0183|cit183","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003562","article-title":"Sildenafil for pulmonary hypertension. (Protocol)","author":"Kanthapillai","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD012621.pub2-BIB0184|cit184","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003562.pub2","article-title":"Phosphodiesterase 5 inhibitors for pulmonary hypertension","author":"Kanthapillai","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD012621.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T18:47:21Z","timestamp":1629485241000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012621.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Airways Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,1,31]]},"references-count":185,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012621.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,31]]}}}